title: Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.
abstract: BACKGROUND
  Helicobacter pylori infection is common in patients with hyperplastic gastric polyps.
  
  
  OBJECTIVE
  To study the effect of eradication of H. pylori on the clinical course of patients with hyperplastic gastric polyps.
  
  
  METHODS
  Single-blind, randomized, controlled trial.
  
  
  METHODS
  University-based gastroenterology outpatient clinic.
  
  
  METHODS
  35 patients with H. pylori infection and hyperplastic gastric polyps at least 3 mm in diameter.
  
  
  METHODS
  Patients were randomly assigned to a treatment group (n = 17), which received a proton-pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium, or to a control group (n = 18), which received no treatment.
  
  
  METHODS
  Patients underwent endoscopy before enrollment and 12 to 15 months after the end of treatment. Serum gastrin levels and titers of IgG to H. pylori were measured.
  
  
  RESULTS
  In the treatment group, the polyps had disappeared by 3 to 15 months (average, 7.1 +/- 1.2 months) after the end of treatment in 12 of all 17 patients (71%) and in 12 of the 15 patients (80%) in whom H. pylori was eradicated. However, 12 to 15 months after the start of the study, no change in polyps or H. pylori status was seen in any controls (P < 0.001). Histologic findings of inflammation and activity, serum gastrin levels, and titers of IgG to H. pylori showed significant regression in the treatment group compared with the control group (P < 0.01).
  
  
  CONCLUSIONS
  Most hyperplastic polyps disappeared after eradication of H. pylori. Thus, eradication should be attempted before endoscopic removal is done in patients with hyperplastic gastric polyps and H. pylori infection.
authors.affiliation: Tokyo Medical and Dental University School of Medicine, Japan. ohmed1@med-tmd.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Ohkusa
authors.forename: I
authors.initials: I
authors.lastname: Takashimizu
authors.forename: K
authors.initials: K
authors.lastname: Fujiki
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Shimoi
authors.forename: T
authors.initials: T
authors.lastname: Horiuchi
authors.forename: T
authors.initials: T
authors.lastname: Sakurazawa
authors.forename: K
authors.initials: K
authors.lastname: Ariake
authors.forename: K
authors.initials: K
authors.lastname: Ishii
authors.forename: J
authors.initials: J
authors.lastname: Kumagai
authors.forename: T
authors.initials: T
authors.lastname: Tanizawa
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004224:Diterpenes / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005755:Gastrins / Q000097:blood; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000276:immunology; D006801:Humans; D006965:Hyperplasia; D007074:Immunoglobulin G / Q000097:blood; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D011127:Polyps / Q000473:pathology*; D054328:Proton Pump Inhibitors; D016037:Single-Blind Method; D018709:Statistics, Nonparametric; D013274:Stomach Neoplasms / Q000473:pathology*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000900:Anti-Bacterial Agents; D004224:Diterpenes; D005755:Gastrins; D007074:Immunoglobulin G; D010406:Penicillins; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; C061681:ecabet; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole